A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Aliskiren in Patients With Diabetes and Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg and Hydrochlorothiazide 25 mg.

Trial Profile

A 12-Week, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Aliskiren in Patients With Diabetes and Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg and Hydrochlorothiazide 25 mg.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2011

At a glance

  • Drugs Aliskiren; Valsartan/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2011 Results published in the American Journal of Cardiovascular Drugs.
    • 14 Jan 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 11 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top